TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06589440: Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Sponsor: Stingray Therapeutics · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 70 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT06589440 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06589440 Rescue Dossier →